Diffuse Large B-Cell Lymphoma Test Your Knowledge

Test Your Knowledge

Quiz: Does High-Dose Methotrexate Have Better CNS Relapse Control in DLBCL?

02/25/2022

True or false: A multicenter analysis has clarified that high-dose methotrexate is associated with better CNS relapse control, but only for high-risk patients with DLBCL.

True or false: A multicenter...

02/25/2022

Oncology

Test Your Knowledge

Quiz: Is Post-ASCT Pembrolizumab Therapy Associated With Elevated Circulating DCs for cHL, DLBCL?

02/11/2022

True or false: Post-ASCT pembrolizumab maintenance therapy is associated with a persistent elevation of circulating DCs in patients with cHL and DLBCL.

True or false: Post-ASCT...

02/11/2022

Oncology

Test Your Knowledge

Quiz: Is Polatuzumab Vedotin a Salvage Option for R/R DLBCL?

02/07/2022

True or false: Polatuzumab vedotin combined with either bendamustine-rituximab or other intensive chemotherapy is not an effective salvage option for patients with R/R DLBCL.

True or false: Polatuzumab...

02/07/2022

Oncology

Test Your Knowledge

Quiz: Is EFS a Surrogate Endpoint for OS for Refractory LBCL?

01/31/2022

True or false: Data from a pivotal study on axicabtagene ciloleucil supports the use of EFS as a surrogate endpoint for long-term OS in refractory LBCL.

True or false: Data from a...

01/31/2022

Oncology

Quiz

Quiz: Will the S1918 Trial Impact the Standard of Care in DLBCL?

01/28/2022

True or false: The S1918 study has the potential to change the standard of care for patients with DLBCL.

True or false: The S1918 study...

01/28/2022

Oncology

Test Your Knowledge

Quiz: Do CD19-7x19 CAR-T Cells Plus Anti-PD-1 Antibody Show Feasibility in Patients With R/R DLBCL?

01/27/2022

True or false: Preliminary data from a phase 1b trial found CD19-7x19 CAR-T cells combined with an anti-PD-1 antibody shows feasibility in patients with R/R DLBCL.

True or false: Preliminary data...

01/27/2022

Oncology

Test Your Knowledge

Quiz: SWOG Trials Highlight Extranodal Presentation in Limited Stage DLBCL

12/22/2021

Fill in the blank: Patients with LS DLBCL treated on 3 SWOG studies had ______ PFS and OS, regardless of extranodal versus nodal presentation.

Fill in the blank: Patients with...

12/22/2021

Oncology

Test Your Knowledge

Quiz: Rituximab Plus Chemo Approved for Which Type of Cancer?

12/20/2021

In December 2021, the FDA approved the combination of rituximab plus chemotherapy for previously untreated pediatric patients with advanced stage CD20-positive DLBCL, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

In December 2021, the FDA...

12/20/2021

Oncology

Test Your Knowledge

Quiz: Which Treatment Received FDA Approved for Certain Pediatric Cancers?

12/03/2021

The FDA recently approved which of the following treatments for pediatric patients with advanced stage CD20+ DLBCL, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

The FDA recently approved which...

12/03/2021

Oncology

Test Your Knowledge

Quiz: What is the Expected OS Rate of Patients With R/R DLBCL?

12/02/2021

True or false: 95% of patients with R/R DLBCL who have received 2 or more lines of prior therapy have an expected OS of more than 2 years.

True or false: 95% of patients...

12/02/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology